Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Stig Johan Wiklund"'
Publikováno v:
Digital Biomarkers, Vol 6, Iss 2, Pp 36-46 (2022)
Introduction: Digital biomarkers have significant potential to transform drug development, but only a few have contributed meaningfully to bring new treatments to market. There are uncertainties in how they will generate quantifiable benefits in clin
Externí odkaz:
https://doaj.org/article/6d0d14bc0b6a49379c5fc0da28bea809
Publikováno v:
Journal of Mathematics in Industry, Vol 11, Iss 1, Pp 1-14 (2021)
Abstract Project selection for a portfolio is a pivotal decision in the pharmaceutical industry. In this paper, we study a portfolio optimization problem for pharmaceutical companies considering the uncertainty of the cost of each phase of drug devel
Externí odkaz:
https://doaj.org/article/08fe2edc80f84f12b098077d85d36bc0
Autor:
Stig Johan Wiklund
Publikováno v:
PLoS ONE, Vol 14, Iss 8, p e0220812 (2019)
The development of a new drug is an extremely high-risk enterprise. The attrition rates of development projects and the average costs for each launched product are daunting, and the completion of a development program requires a very long time horizo
Externí odkaz:
https://doaj.org/article/9422d39d25d94d08ab00810d3b528118
Autor:
Stig Johan Wiklund
Publikováno v:
Journal of Biopharmaceutical Statistics. 31:788-808
The discouragingly high rates of attrition in drug development, and in particular in Phase 2, warrant a closer look at the decision criteria applied for investment in the next phase (Phase 3). We have in this article evaluated Stop/Go criteria after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6fd4eb18cca4e98be9b710a82891af6
https://doi.org/10.1080/10543406.2021.1975129
https://doi.org/10.1080/10543406.2021.1975129
Publikováno v:
Journal of Mathematics in Industry, Vol 11, Iss 1, Pp 1-14 (2021)
Project selection for a portfolio is a pivotal decision in the pharmaceutical industry. In this paper, we study a portfolio optimization problem for pharmaceutical companies considering the uncertainty of the cost of each phase of drug development an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::218aec650008bf992c2bf2be135f63ca
https://doaj.org/article/08fe2edc80f84f12b098077d85d36bc0
https://doaj.org/article/08fe2edc80f84f12b098077d85d36bc0
Publikováno v:
Pharmaceutical statistics. 20(6)
When making decisions regarding the investment and design for a Phase 3 programme in the development of a new drug, the results from preceding Phase 2 trials are an important source of information. However, only projects in which the Phase 2 results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a2855da63de5fdde0aedb2b3cafafc9
https://pubmed.ncbi.nlm.nih.gov/34002467
https://pubmed.ncbi.nlm.nih.gov/34002467
Autor:
Niclas Sjögren, Stig Johan Wiklund
Publikováno v:
Drug Information Journal. 45:759-765
The rapidly increasing cost to develop new drugs calls for new tools that efficiently enable the demonstration of the safety and effectiveness of a new drug. When validating such a decision-enabling tool, a traditional approach is typically to apply
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::614ae1b36e169df85bfc8729e29b416d
https://doi.org/10.1177/009286151104500512
https://doi.org/10.1177/009286151104500512
Publikováno v:
Pharmaceutical Statistics. 10:508-516
Modelling and simulation (M&S) is increasingly being applied in (clinical) drug development. It provides an opportune area for the community of pharmaceutical statisticians to pursue. In this article, we highlight useful principles behind the applica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::299cd0066d5d1f22c3d443eed26cedac
https://doi.org/10.1002/pst.523
https://doi.org/10.1002/pst.523
Autor:
Stig Johan Wiklund
Publikováno v:
Drug Development Research. 73:24-34
In the pharmaceutical industry, it is common practice to pursue sequentially, within a family of compounds, a number of candidate compounds for further development. This article challenges the sequential tradition, and instead proposes a parallel dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::836c2b9b567ec6ad32a89bac9f790353
https://doi.org/10.1002/ddr.20446
https://doi.org/10.1002/ddr.20446
Autor:
Lars B. Nilsson, Göran Eklund, Stig Johan Wiklund, Göran Duker, Ahmad Al-Saffar, Tomas Forsberg, Johan Gabrielsson, Anna H. Persson, Anna Ollerstam, J. Magnus Fredriksson, Sandra A.G. Visser
Publikováno v:
Journal of Pharmacological and Toxicological Methods. 55:35-48
Introduction: Drug-induced QT interval prolongation may lead to ventricular arrhythmias. The aim of the study was to optimize QT interval data processing to quantify drug-induced QT interval prolongation in the telemetry instrumented conscious dog mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dea178a75325028559170c347f76cfad
https://doi.org/10.1016/j.vascn.2006.02.009
https://doi.org/10.1016/j.vascn.2006.02.009